SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced FDA acceptance of its NDA with Priority Review for…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed May 27, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 27, 2026 at 07:30 ET

BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of November 27, 2026. The FDA is not planning an advisory committee meeting, and the company is poised to launch upon approval. This is a major regulatory milestone for a first-in-class therapy addressing a significant unmet need in a rare, progressive muscular dystrophy.

  • FDA accepted NDA for BBP-418 with Priority Review; PDUFA target action date November 27, 2026.
  • FDA not currently planning an advisory committee meeting to discuss the application.
  • BBP-418 met all primary and secondary endpoints in Phase 3 FORTIFY trial at 12-month interim analysis.
  • If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access